Effect of naturally random allocation to lower low-density lipoprotein cholesterol on the risk of coronary heart disease mediated by polymorphisms in NPC1L1, HMGCR, or Both: A 2 × 2 factorial mendelian randomization study

Journal of the American College of Cardiology

Volumn 65, Issue 15, 2015, Pages 1552-1561

  Ference, Brian A ^a   Majeed, Faisal ^a   Penumetcha, Raju ^a   Flack, John M ^a   Brook, Robert D ^b  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

ezetimibe; genetic association; PCSK9; statins

Indexed keywords

BINDING PROTEIN; EZETIMIBE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NIEMANN PICK C1 LIKE 1 PROTEIN; PLACEBO; UNCLASSIFIED DRUG; HMGCR PROTEIN, HUMAN; MEMBRANE PROTEIN; NPC1L1 PROTEIN, HUMAN;

ARTICLE; CARDIOVASCULAR RISK; CASE CONTROL STUDY; COHORT ANALYSIS; EFFECT SIZE; FACTORIAL DESIGN; GENE; GENE LINKAGE DISEQUILIBRIUM; GENETIC POLYMORPHISM; HEART INFARCTION; HMGCR GENE; HUMAN; ISCHEMIC HEART DISEASE; META ANALYSIS; NPC1L1 GENE; PRIORITY JOURNAL; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK ASSESSMENT; RISK REDUCTION; TREATMENT OUTCOME; BLOOD; CORONARY ARTERY DISEASE; FEMALE; GENETIC PREDISPOSITION; GENETICS; MALE; MENDELIAN RANDOMIZATION ANALYSIS; MIDDLE AGED;

CHOLESTEROL, LDL; CORONARY DISEASE; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; HYDROXYMETHYLGLUTARYL COA REDUCTASES; MALE; MEMBRANE PROTEINS; MENDELIAN RANDOMIZATION ANALYSIS; MIDDLE AGED; POLYMORPHISM, GENETIC; RISK ASSESSMENT;

EID: 84928026823     PISSN: 07351097     EISSN: 15583597     Source Type: Journal    
DOI: 10.1016/j.jacc.2015.02.020     Document Type: Article

References (25)

1. Prospective Studies Collaboration S. Lewington, and G. Whitlock Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55,000 vascular deaths Lancet 370 2007 1829 1839
2. Emerging Risk Factors Collaboration E. Di Angelantonio, and N. Sarwar Major lipids, apolipoproteins, and risk of vascular disease JAMA 302 2009 1993 2000
3. B.A. Ference, W. Yoo, and I. Alesh Effect of long-term exposure to lower low-density lipoprotein cholesterol beginning early in life on the risk of coronary heart disease: a Mendelian randomization analysis J Am Coll Cardiol 60 2012 2631 2639
4. Cholesterol Treatment Trialists' (CTT) Collaboration Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials Lancet 376 2010 1670 1681
5. AIM-HIGH Investigators Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy N Engl J Med 365 2011 2255 2267
6. HPS2-THRIVE Collaborative Group Effects of extended-release niacin with laropiprant in high-risk patients N Engl J Med 371 2014 203 212
7. ACCORD Study Group Effects of combination lipid therapy in type 2 diabetes mellitus N Engl J Med 362 2010 1563 1574
8. M. Garcia-Calvo, J. Lisnock, and H.G. Bull The target of ezetimibe is Niemann-Pick C1-Like 1 (NPC1L1) Proc Natl Acad Sci U S A 102 2005 8132 8137
9. C.P. Cannon, R.P. Giugliano, M.A. Blazing for the IMPROVE-IT Investigators Rationale and design of IMPROVE-IT (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial): comparison of ezetimibe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes in patients with acute coronary syndromes Am Heart J 156 2008 826 832
10. M.A. Blazing, R.P. Giugliano, and C.P. Cannon Evaluating cardiovascular event reduction with ezetimibe as an adjunct to simvastatin in 18,144 patients after acute coronary syndromes: final baseline characteristics of the IMPROVE-IT study population Am Heart J 168 2014 205 212.e1
11. M.D. Mailman, M. Feolo, and Y. Jin The NCBI dbGaP database of genotypes and phenotypes Nat Genet 39 2007 1181 1186
12. Global Lipids Genetics Consortium C.J. Willer, and E.M. Schmidt Discovery and refinement of loci associated with lipid levels Nat Genet 45 2013 1274 1283
13. T.M. Teslovich, K. Musunuru, and A.V. Smith Biological, clinical and population relevance of 95 loci for blood lipids Nature 466 2010 707 713
14. S. Kathiresan, O. Melander, and C. Guiducci Six new loci associated with blood low-density lipoprotein cholesterol, high-density lipoprotein cholesterol or triglycerides in humans Nat Genet 40 2008 189 197
15. 1000 Genomes Project Consortium G.R. Abecasis, and A. Auton An integrated map of genetic variation from 1,092 human genomes Nature 491 2012 56 65
16. CARDIoGRAMplusC4D Consortium P. Deloukas, and S. Kanoni Large-scale association analysis identifies new risk loci for coronary artery disease Nat Genet 45 2013 25 33
17. CARDIOGRAMPLYSC4D Consortium. Wellcome Trust Sanger Institute. Available at: http://www.CARDIOGRAMPLUSC4D.org. Accessed February 10, 2015.
18. SNP & Variation Suite (Version 8.1.4). Golden Helix, Inc. Available at: http://www.goldenhelix.com/SNP-Variation/index.html. Accessed February 10, 2015.
19. B.N. Howie, P. Donnelly, and J. Marchini A flexible and accurate genotype imputation method for the next generation of genome-wide association studies PLoS Genetics 5 2009 e1000529
20. D.A. Lawlor, R.M. Harbord, and J.A. Sterne Mendelian randomization: using genes as instruments for making causal inferences in epidemiology Stat Med 27 2008 1133 1163
21. Myocardial Infarction Genetics Consortium Investigators Inactivating mutations in NPC1L1 and protection from coronary heart disease N Engl J Med 371 2014 2072 2082
22. Cannon CP, for the IMPROVE-IT Investigators. IMPROVE-IT Trial: A Comparison of Ezetimibe/Simvastatin versus Simvastatin Monotherapy on Cardiovascular Outcomes After Acute Coronary Syndromes. Paper presented at: American Heart Association Scientific Sessions; November 17, 2014; Chicago, IL.
23. R.T. Dadu, and C.M. Ballantyne Lipid lowering with PCSK9 inhibitors Nat Rev Cardiol 11 2014 563 575
24. B.F. Voight, G.M. Peloso, and M. Orho-Melander Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomization study Lancet 380 2012 5572 5580
25. D. Morrone, W.S. Weintraub, and P.P. Toth Lipid-altering efficacy of ezetimibe plus statin and statin monotherapy and identification of factors associated with treatment response: a pooled analysis of over 21,000 subjects from 27 clinical trials Atherosclerosis 223 2012 251 261